Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of “Buy” by Analysts

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) have been given an average recommendation of “Buy” by the ten analysts that are covering the firm, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $27.89.

Several research analysts have recently weighed in on CNTA shares. Chardan Capital started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They set a “buy” rating and a $30.00 price target on the stock. Needham & Company LLC started coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They set a “buy” rating and a $35.00 price target on the stock. Guggenheim reiterated a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley reiterated an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd.

Insider Transactions at Centessa Pharmaceuticals

In related news, General Counsel Iqbal J. Hussain sold 2,080 shares of the stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $14.01, for a total transaction of $29,140.80. Following the completion of the sale, the general counsel now owns 105,386 shares of the company’s stock, valued at $1,476,457.86. This represents a 1.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Arjun Goyal bought 44,939 shares of the firm’s stock in a transaction that occurred on Thursday, May 15th. The shares were purchased at an average cost of $12.24 per share, with a total value of $550,053.36. Following the transaction, the director now directly owns 44,939 shares of the company’s stock, valued at $550,053.36. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders sold 162,398 shares of company stock valued at $2,109,252. Company insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of CNTA. Janus Henderson Group PLC lifted its position in Centessa Pharmaceuticals by 279.2% during the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after acquiring an additional 3,614,623 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Centessa Pharmaceuticals by 35.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 6,954,000 shares of the company’s stock valued at $99,999,000 after acquiring an additional 1,834,973 shares during the last quarter. Foresite Capital Management VI LLC acquired a new position in Centessa Pharmaceuticals during the 4th quarter valued at approximately $20,994,000. Point72 Asset Management L.P. increased its stake in Centessa Pharmaceuticals by 26.2% during the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company’s stock valued at $57,396,000 after purchasing an additional 710,936 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Centessa Pharmaceuticals by 14.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company’s stock valued at $89,854,000 after purchasing an additional 685,371 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Price Performance

Shares of CNTA opened at $12.43 on Friday. The company has a market capitalization of $1.66 billion, a P/E ratio of -6.87 and a beta of 1.48. The company has a quick ratio of 14.37, a current ratio of 14.37 and a debt-to-equity ratio of 0.28. The firm has a 50 day moving average of $12.70 and a 200 day moving average of $14.87. Centessa Pharmaceuticals has a twelve month low of $8.46 and a twelve month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.15. As a group, equities research analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.